Administration of vorinostat disrupts HIV-1 latency in patients on antiretroviral therapy

The latent HIV-1 reservoir represents a major barrier to curing patients with HIV-1 infection, and now in vivo evidence is presented that vorinostat can disrupt proviral latency of HIV-1.